REFRACTORY T-CELL NON-HODGKIN LYMPHOMA
Clinical trials for REFRACTORY T-CELL NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY T-CELL NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY T-CELL NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug cocktail shows promise for tough lymphomas
Disease control CompletedThis early-phase study tested the safety and best dose of adding olaparib to high-dose chemotherapy for people with lymphomas that returned or didn't respond to treatment. 50 adults aged 18-65 took part. The goal was to see if this combination could work better before a stem cell…
Matched conditions: REFRACTORY T-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 20, 2026 11:54 UTC
-
New combo therapy shows promise for tough lymphoma cases
Disease control CompletedThis study tested a combination of pembrolizumab (an immunotherapy drug) and targeted radiation in 17 patients with non-Hodgkin lymphoma that had returned or stopped responding to treatment. The goal was to see if adding radiation could help the immune system fight the cancer bet…
Matched conditions: REFRACTORY T-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 13, 2026 16:00 UTC